ABBV ABBVIE INC

2026Q1 · CUSIP 00287Y109 · Big Pharma · Sector: Healthcare & Biotech

Danger · Dual-confirm: breadth + price

Holders

4,029

Δ holders QoQ

-61

Breadth percentile

Top 98%

Whale holders

359

Δ whales

-1

Inst. holding value

$268.4B

New positions

204

Closed positions

265

Price momentum (1Q)

-9.3%

Put / Call

51/50

Breadth history (34 quarters)

Past Lit Events & Aftermath 17 lit events

Period	Percentile	Next-1Q return	Next-2Q return
2025Q4	Top 1%	-9.3%	—
2025Q3	Top 1%	-3.4%	-7.8%
2025Q1	Top 1%	+12.0%	+28.0%
2024Q4	Top 1%	-4.5%	+7.0%
2024Q3	Top 0%	+22.7%	+11.8%
2024Q1	Top 4%	+19.4%	+0.9%
2023Q4	Top 1%	-5.4%	+13.0%
2023Q3	Top 3%	+28.3%	+21.3%
2022Q4	Top 0%	-3.2%	+2.5%
2022Q1	Top 1%	-7.8%	+0.8%
2021Q4	Top 0%	+5.4%	-1.4%
2021Q2	Top 2%	-0.0%	+23.5%
2020Q4	Top 1%	+13.5%	+16.3%
2020Q2	Top 0%	+4.2%	+13.1%
2019Q4	Top 0%	-0.8%	+5.7%
2018Q4	Top 1%	+0.4%	-15.0%
2018Q1	Top 9%	-5.8%	-14.4%

Show all 17 events

Options Sentiment

Put holders

QoQ: +3

Call holders

QoQ: -1

See methodology →

Fundamentals

PE (TTM)

125.4

EPS (TTM)

$2.03

EPS YoY

-13.6%

Revenue (TTM)

$62.8B

Revenue YoY

+9.5%

Net margin

5.8%

ROE

—

Debt ratio

104.9%

FCF (TTM)

$20.0B

Dividend (TTM)

$6.74

Quarterly Revenue & EPS (4Y)

Quarterly figures; EPS split-adjusted, early quarters hidden when not calibrable

P/E (TTM) over time

P/E = close 47 days after quarter-end (filing date) ÷ TTM EPS then; loss quarters hidden

As of 2026-03-31 · SEC filings (XBRL)

Get the next update

2026Q2 holdings publish around Aug 15 — subscribe to receive the lists first.